CEO Converts Preferred Shares, Boosting Direct Stake by 55 Million Shares
QUCY has more than doubled off its 52-week low of $0.3.
Summary
Quantum Cyber CEO David E. Lazar converted preferred shares into 55 million ordinary shares at no cost, massively increasing his direct equity stake amid the company's pivot to cybersecurity.
Key Events · Ownership and Investor Activity · QUCY
-
CEO Converts Preferred Shares
On August 5, 2026, David E. Lazar converted all Series A, B, and C Preferred Shares and 124,700 Series D Preferred Shares into 55,057,500 Ordinary Shares at no additional cost.
-
Massive Stake Increase
Following the conversion, Lazar directly holds 55,057,500 Ordinary Shares—a dramatic increase from his prior holdings that significantly concentrates voting power.
-
Conversion Prices Far Above Market
Although the conversion prices ranged from $9.00 to $225.00 per share, vastly exceeding the current stock price of $1.47, the transaction required no cash outlay thanks to prior shareholder approval.
-
Strategic Context
The conversion occurs as Quantum Cyber pivots from life sciences to cyber/drones, following a $250 million shelf registration, heavy insider selling, and a dilutive IP acquisition.
Analysis · QUCY · Life Sciences
CEO David E. Lazar converted all of his Series A, B, and C Preferred Shares, along with a portion of Series D, into 55,057,500 Ordinary Shares at no additional cost. The conversion prices ranged from $9.00 to $225.00 per share—far above the current stock price of $1.47—but the transaction was structured as a no-cost conversion following shareholder approval in April 2026. This dramatically increases Lazar's direct equity stake to 55 million shares, aligning his interests with shareholders while also concentrating voting power. The move comes amid Quantum Cyber's radical pivot from life sciences to cyber/drones, a period marked by heavy dilution, insider selling, and a $250 million shelf registration. The conversion signals the CEO's long-term commitment to the new strategy, though the sheer size of the stake raises governance considerations.
At the time of this filing, QUCY was trading at $1.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $32.8M. The 52-week trading range was $0.30 to $4.93. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.